Lavocestine (Carbocisteine)

Carbocisteine reduces mucus viscosity by breaking disulfide bonds in mucopolysaccharide fibers. This chemical modification makes the mucus less elastic, allowing the cilia of the respiratory epithelium to move the secretions more efficiently toward the throat for expectoration.

The appropriate dose of Lavocestine is determined by the prescribing healthcare professional based on the patient’s age, clinical condition, and response to therapy. Dosage recommendations are provided in the product labeling and should be followed exactly as instructed by the prescriber.

Safety data for carbocisteine in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Lavocestine, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lavocestine (carbocisteine) differs from agents such as N‑acetylcysteine by primarily cleaving disulfide bonds in mucus polymers rather than acting as a precursor of glutathione. It is generally well tolerated and does not possess the strong bronchodilatory or antioxidant properties seen with some alternatives, making it a suitable option for patients who need mucus thinning without additional pharmacologic effects.

Lavocestine should be stored at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, direct sunlight and extreme temperature fluctuations to maintain stability and potency throughout its shelf life.

Lavocestine is taken orally, usually in tablet or syrup form, as directed by the prescribing clinician. It should be swallowed with a glass of water and can be taken with or without food, unless specific instructions are provided on the label.

The most serious adverse reactions reported with carbocisteine include severe allergic responses such as rash, urticaria or anaphylaxis, as well as rare cases of hepatic dysfunction and blood‑cell abnormalities like neutropenia. Patients should seek immediate medical attention if they experience any signs of a serious reaction.

Lavocestine should be avoided in individuals with a known hypersensitivity to carbocisteine or any other thiol‑containing compounds. Caution is also advised for patients with severe renal or hepatic impairment, and it should only be used in pregnancy or lactation when clearly indicated by a healthcare professional.